UroGen Pharma Ltd. — Director's Dealing 2019

Jan 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: BENTSUR RON (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	38113	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Unit	$		Ordinary Shares (92768)		Direct
Employee Stock Option (right to buy)	$19.55	2027-06-28	Ordinary Shares (80000)		Direct
Employee Stock Option (right to buy)	$43.67	2028-01-10	Ordinary Shares (50000)		Direct

Footnotes

F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter.

F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017.

F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018.